Status:
COMPLETED
Prevalence, Intensity and Consequences of Bortezomib-induced Neuropathic Disorders.
Lead Sponsor:
University Hospital, Clermont-Ferrand
Conditions:
Chemotherapy Induced Peripheral Neuropathy
Multiple Myeloma
Eligibility:
All Genders
18+ years
Brief Summary
Cancer-induced peripheral neuropathies (CIPN) remain a real problem in oncology (Balayssac et al., 2011). These CIPN are induced by certain classes of anticancer drugs such as taxanes (paclitaxel and ...
Detailed Description
Only 2 studies evaluated quantitatively and qualitatively the sensitivity disorders in patients with bortezomib-induced peripheral neuropathy by intravenous (Boyette-Davis et al., 2011; Cata et al., 2...
Eligibility Criteria
Inclusion
- \- Patients previously treated with bortezomib for multiple myeloma between 2008 and 2016 at Clermont-Ferrand University Hospital.
- Oral non-opposition of participation in the study
Exclusion
- Patient unable to understand or answer questionnaires.
- Age \< 18 years.
- Neurological pathologies (e. g. Parkinson's syndrome, stroke, fibromyalgia, etc.).
- Legal incapacity (person deprived of liberty or under guardianship).
Key Trial Info
Start Date :
January 15 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 31 2020
Estimated Enrollment :
67 Patients enrolled
Trial Details
Trial ID
NCT03344328
Start Date
January 15 2019
End Date
January 31 2020
Last Update
November 12 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Clermont-Ferrand
Clermont-Ferrand, France, 63003